Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective

被引：1
|
作者：
Hastings, V.
Delea, T. E.
Amonkar, M.
Lykopoulos, K.
Diaz, J.
Johnston, S. R.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] GlaxoSmithKline, Collegeville, PA USA
[3] GlaxoSmithKline Global Hlth Outcomes, London, England
[4] GlaxoSmithKline Hllth Outcomes Oncol, London, England
[5] Royal Marsden NHS Fdn Trust, Inst Canc Res, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
    K. Matter-Walstra
    M. Schwenkglenks
    K. J. Dedes
    Breast Cancer Research and Treatment, 2017, 163 : 635 - 635
  • [42] Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
    Matter-Walstra, K.
    Schwenkglenks, M.
    Dedes, K. J.
    BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 635 - 635
  • [43] COST EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE VERSUS PALBOCICLIB PLUS LETROZOLE FOR THE TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER2-) ADVANCED OR METASTATIC BREAST CANCER FROM A US PRIVATE THIRD-PARTY PAYER PERSPECTIVE
    Suri, G.
    Mistry, R.
    Young, K. C.
    Hettle, R.
    May, J. R.
    Brixner, D.
    Oderda, G.
    Biskupiak, J.
    Tang, D.
    Bhattacharyya, D.
    Bhattacharyya, S.
    Mishra, D.
    Dalal, A.
    VALUE IN HEALTH, 2017, 20 (09) : A436 - A436
  • [44] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in the United States.
    Masurkar, Prajakta P.
    Damgacioglu, Haluk
    Deshmukh, Ashish
    Trivedi, Meghana
    CANCER RESEARCH, 2021, 81 (13)
  • [45] Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2− advanced breast cancer receiving first-line ribociclib plus fulvestrant
    P. Neven
    P. A. Fasching
    S. Chia
    G. Jerusalem
    M. De Laurentiis
    S.-A. Im
    K. Petrakova
    G. V. Bianchi
    M. Martín
    A. Nusch
    G. S. Sonke
    L. De la Cruz-Merino
    J. T. Beck
    J. P. Zarate
    Y. Wang
    A. Chakravartty
    C. Wang
    D. J. Slamon
    Breast Cancer Research, 25
  • [46] Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2-advanced breast cancer receiving first-line ribociclib plus fulvestrant
    Neven, P.
    Fasching, P. A.
    Chia, S.
    Jerusalem, G.
    De Laurentiis, M.
    Im, S. -a.
    Petrakova, K.
    Bianchi, G. V.
    Martin, M.
    Nusch, A.
    Sonke, G. S.
    de la Cruz-merino, L.
    Beck, J. T.
    Zarate, J. P.
    Wang, Y.
    Chakravartty, A.
    Wang, C.
    Slamon, D. J.
    BREAST CANCER RESEARCH, 2023, 25 (01)
  • [47] COST-EFFECTIVENESS ANALYSIS OF RIBOCICLIB VERSUS ABEMACICLIB IN THE FIRST-LINE (1L) TREATMENT OF POSTMENOPAUSAL WOMEN WITH HR+/HER2-ADVANCED BREAST CANCER (ABC)
    Cameron, D.
    Sharma, V.
    Biswas, C.
    Clarke, C.
    Chandiwana, D.
    Pathak, P.
    VALUE IN HEALTH, 2022, 25 (12) : S126 - S126
  • [48] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC): MONALEESA-2 safety results.
    Janni, Wolfgang
    Burris, Howard A.
    Blackwell, Kimberly L.
    Hart, Lowell L.
    Chan, Arlene
    Nusch, Arnd
    Burdaeva, Olga Nikolaevna
    Alba, Emilio
    Yardley, Denise A.
    Bachelot, Thomas Denis
    Gil, Miguel J. Gil
    Richards, Donald A.
    Sparano, Joseph A.
    Kattan, Joseph Gergi
    Bourgeois, Hugues Pierre
    El Karak, Fadi Rafic
    Ramaswamy, Bhuvaneswari
    Sutradhar, Santosh C.
    Miller, Michelle Kristine
    Conte, Pier Franco
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [49] First-line trastuzumab (Herceptin® plus docetaxel versus docetaxel alone in women with HER2-positive metastatic breast cancer (MBC):: results from a randomised phase II trial (M77001).
    Extra, JM
    Cognetti, F
    Chan, S
    Maraninchi, D
    Synder, R
    Anton, A
    Mefti, F
    Grimes, D
    Mayne, K
    Meyer-Wenger, A
    Marty, M
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S47 - S48
  • [50] Impact of Palbociclib plus Letrozole on Health Related Quality of Life (HRQOL) compared with Letrozole alone in first-line Postmenopausal Patients with ER+HER2-Metastatic Breast Cancer (MBC): Results from PALOMA-2 Bone Metastases Subgroup
    Ettl, J.
    Harbeck, N.
    Gelmon, K.
    Mori, A.
    Lu, D.
    Bhattacharyya, H.
    Iyer, S.
    Finn, R. S.
    Rugo, H.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S119 - S120
12345